Product
Atomoxetine
Aliases
Atomoxetine hydrochloride, Atomoxetine Hydrochloride, Strattera
Name
Strattera
INN Name
ATOMXETINE HYROCHLORIDE
FDA Approved
Yes
21 clinical trials
22 organizations
18 indications
4 documents
Indication
ADHDIndication
DyslexiaIndication
Obstructive Sleep ApneaIndication
HypertensionIndication
TachycardiaIndication
Chronic Orthostatic IntoleranceIndication
Attention Deficit Hyperactivity DisorderIndication
Parkinson's DiseaseIndication
IdiopathicIndication
Sleep ApneaIndication
obstructive sleep apneaIndication
Vasovagal SyncopeIndication
Intermittent Explosive DisorderIndication
Executive DysfunctionIndication
Neurogenic Orthostatic HypotensionIndication
ObesityIndication
MorbidIndication
Alcohol Use DisorderClinical trial
A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity DisorderStatus: Recruiting, Estimated PCD: 2027-06-28
Clinical trial
Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep ApneaStatus: Completed, Estimated PCD: 2022-07-20
Clinical trial
Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tasks Pre- and Post-Atomoxetine TreatmentStatus: Completed, Estimated PCD: 2016-07-01
Clinical trial
Phase 2 Randomized Double-Blind Placebo-Controlled 4-Period Single-Dose Crossover Factorial Study to Evaluate the Contribution of the Individual Drug Components to the Efficacy of AD109 in Obstructive Sleep ApneaStatus: Completed, Estimated PCD: 2021-05-28
Clinical trial
Open-Label 4-Period Dose-Escalation Safety and Efficacy Study of AD313 in Participants With Obstructive Sleep ApneaStatus: Completed, Estimated PCD: 2022-04-18
Clinical trial
Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or AtomoxetineStatus: Completed, Estimated PCD: 2020-12-01
Clinical trial
Randomized Double-Blind 2-Period Multiple Dose Crossover Study to Evaluate the Efficacy and Safety of AD113 vs Atomoxetine in OSA Patients With HypertensionStatus: Completed, Estimated PCD: 2023-01-31
Clinical trial
Treatment of Orthostatic IntoleranceStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin TherapyStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Pharmacological Treatment of ADHD in Young ChildrenStatus: Completed, Estimated PCD: 2008-08-01
Clinical trial
TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease: A Single Center, Randomized Pilot StudyStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Novel Pharmacological Therapy for Obstructive Sleep ApneaStatus: Recruiting, Estimated PCD: 2023-10-20
Clinical trial
The Neuroprotective Effects of Methylphenidate and Atomoxetine in Children With Attention Deficit Hyperactivity Disorder: A Lipidomic StudyStatus: Completed, Estimated PCD: 2021-01-25
Clinical trial
Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep ApneaStatus: Not yet recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Randomized, Prospective, Placebo-Controlled, Crossover Study of Atomoxetine in the Prevention of Vasovagal Syncope (POST7)Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
An Open-Label, Single- and Multi-Dose Study to Evaluate the Relationship Between the Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes of Atomoxetine in CYP2D6 Extensive, Intermediate and Poor Metabolizers in Children With Attention Deficit/Hyperactivity DisorderStatus: Completed, Estimated PCD: 2022-06-01
Clinical trial
Dialectical Behavioral Therapy Skills for Impulsive Aggression in Children Diagnosed With Attention Deficit Hyperactivity Disorder at Alexandria University HospitalsStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure IND117394 12/28/12Status: Completed, Estimated PCD: 2021-05-12
Clinical trial
Bariatric Surgery and Pharmacokinetics of Atomoxetine: BAR-MEDS AtomoxetineStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD RiskStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Enhancing the Effects of Adolescent Alcohol Treatment With AtomoxetineStatus: Active (not recruiting), Estimated PCD: 2023-06-01
Document
DailyMed Label: StratteraOrganization
Lake Erie Medical DBA Quality Care Products LLCOrganization
Sandoz Inc. Document
DailyMed Label: Atomoxetine
Organization
Camber Pharmaceuticals, Inc.Organization
A-S Medication SolutionsDocument
DailyMed Label: AtomoxetineOrganization
Dr. Reddy's Laboratories LimitedOrganization
Eli Lilly and Company
Organization
Teva Pharmaceuticals USA, Inc.Organization
AvKAREOrganization
Golden State Medical Supply, Inc.Organization
Major PharmaceuticalsOrganization
Burel Pharmaceuticals, LLCOrganization
Zydus Lifesciences LimitedOrganization
Zydus Pharmaceuticals USA Inc.Organization
bryant ranch prepackOrganization
Rising Pharma Holdings, Inc.Organization
Glenmark Pharmaceuticals Inc., USAOrganization
NORTHSTAR RX LLCOrganization
Apotex Corp.Organization
AvPAKOrganization
American Health PackagingOrganization
Aurobindo Pharma LimitedOrganization
STAT RX USA LLC